First Trust Advisors LP Grows Stock Holdings in Cellebrite DI Ltd. $CLBT

First Trust Advisors LP raised its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 49.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 136,409 shares of the company’s stock after acquiring an additional 44,912 shares during the quarter. First Trust Advisors LP owned about 0.05% of Cellebrite DI worth $1,880,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. Cooper Creek Partners Management LLC bought a new position in shares of Cellebrite DI in the third quarter worth $55,999,000. Capital International Investors bought a new stake in shares of Cellebrite DI during the 4th quarter valued at $41,073,000. Invesco Ltd. lifted its holdings in Cellebrite DI by 58.6% during the 3rd quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock worth $103,030,000 after purchasing an additional 2,054,644 shares in the last quarter. Artisan Partners Limited Partnership purchased a new stake in Cellebrite DI during the 4th quarter worth about $25,871,000. Finally, Pertento Partners LLP boosted its stake in Cellebrite DI by 28.2% in the 4th quarter. Pertento Partners LLP now owns 5,959,324 shares of the company’s stock worth $107,447,000 after purchasing an additional 1,311,109 shares during the period. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Stock Up 3.6%

Cellebrite DI stock opened at $16.01 on Friday. The stock has a market cap of $3.99 billion, a price-to-earnings ratio of 57.18, a PEG ratio of 1.98 and a beta of 1.18. The business has a 50-day simple moving average of $14.55 and a 200 day simple moving average of $14.11. Cellebrite DI Ltd. has a 52 week low of $11.02 and a 52 week high of $19.98.

Analyst Ratings Changes

CLBT has been the topic of several analyst reports. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Needham & Company LLC cut their price objective on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Finally, DA Davidson boosted their price objective on shares of Cellebrite DI from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $21.80.

Insider Activity

In related news, CRO Marcus Jewell sold 12,658 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the sale, the executive directly owned 440,101 shares of the company’s stock, valued at $5,620,089.77. This trade represents a 2.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Thomas E. Hogan sold 103,188 shares of Cellebrite DI stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $15.76, for a total transaction of $1,626,242.88. Following the sale, the chief executive officer owned 590,777 shares of the company’s stock, valued at approximately $9,310,645.52. The trade was a 14.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 158,191 shares of company stock worth $2,479,438. 5.70% of the stock is currently owned by insiders.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.